摘要
目的观察吡柔比星(THP)联合FolFox4方案治疗晚期胃癌的疗效及安全性。方法吡柔比星40mg/m2,静脉注射,d1;奥沙利铂(Oxaliplatin,L-OHP)85～100mg/m2,静脉滴注2～4h,d1;亚叶酸钙200mg/m2,静脉滴注2h;氟脲嘧啶500mg/m2持续静脉泵入22h,d1,2;每3周为一周期,至少完成3周有效。结果47例患者中,CR4例,PR16例,总有效率42.6%。初治患者21例中CR3例,PR7例,有效率47.6%;复治患者26例中CR1例,PR9例,有效率38.4%。临床受益反应(CBP)改善者28例(59.4%)。Ⅲ～Ⅳ度血液学毒性包括中性粒细胞减少2例(4.3%)和血小板减少3例(6.4%);Ⅲ～Ⅳ度非血液学毒性包括恶心呕吐4例(8.5%),口腔黏膜炎2例(4.3%),脱发1例(2.1%)。结论吡柔比星(THP)联合FolFox4方案治疗晚期胃癌疗效较好,毒副反应较低,值得在临床上进一步推广使用。
Objective To evaluate the therapeutic effectiveness and safety of chemotherapeutic regimen containing FolFox4 and pirarubicin （THP） in the treatment of gastric carcinoma in advanced stage. Methods Patients received intravenous injection of 85 - 100 mg/m^2 oxaliplatin for 2 to 4 hours and 40 mg/ m^2 THP on the first day; 200 mg/m^2 calcium folinate for 2 hours and 500 mg/m^2 fluorouracil for 22 hours on the first and second days. Three weeks constituted a cycle, and the treatment could be effective at least after the completion of 3 weeks. Results Of the 47 cases ,4 obtained complete remission and 16 partial response. The total response rate was 42.6%. Of the 21 cases treated for the first time,3 obtained complete remission and 7 partial response,the total response rate was 47.6%. Of the 26 retreated cases 1 obtained complete remission and 9 partial response, the total response rate was 38.4%. Twenty-eight patients were improved in CBP（ 59.4% ）. Of all cases of hematological toxicity of third to fourth degree,2 had neutropenia （4.3%）, 3 had thrombocytopenia（6.4% ）. Of all cases of non-hematological toxicity of third to fourth degree,4 had nausea and vomitting（8.5% ） ,2 had stomatitis（4.3% ）, 1 had alopecia（2.1% ）. Conclusions Regimen Fol-Fox4 with THP is effective in the treatment of gastric carcinoma in advanced stage, the side effect is mild, and is worthy of clinical application and extension.
出处
《中国肿瘤临床与康复》
2008年第1期71-73,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
